NASDAQ:ZNTL Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis $4.47 +0.11 (+2.52%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.30▼$4.6250-Day Range$3.48▼$11.9852-Week Range$3.27▼$29.03Volume437,684 shsAverage Volume1.07 million shsMarket Capitalization$317.49 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Zentalis Pharmaceuticals alerts: Email Address Zentalis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside153.5% Upside$11.33 Price TargetShort InterestBearish14.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 4 Articles This WeekInsider TradingSelling Shares$157,325 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.72) to ($3.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.08 out of 5 starsMedical Sector625th out of 936 stocksPharmaceutical Preparations Industry287th out of 436 stocks 4.1 Analyst's Opinion Consensus RatingZentalis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 3 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageZentalis Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zentalis Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.67% of the outstanding shares of Zentalis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverZentalis Pharmaceuticals has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Zentalis Pharmaceuticals has recently increased by 8.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZentalis Pharmaceuticals does not currently pay a dividend.Dividend GrowthZentalis Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZNTL. Previous Next 2.4 News and Social Media Coverage News SentimentZentalis Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Zentalis Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ZNTL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows5 people have added Zentalis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zentalis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $157,325.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Zentalis Pharmaceuticals is held by insiders.Read more about Zentalis Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zentalis Pharmaceuticals are expected to decrease in the coming year, from ($2.72) to ($3.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zentalis Pharmaceuticals is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zentalis Pharmaceuticals is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZentalis Pharmaceuticals has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Zentalis Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.Read More ZNTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZNTL Stock News HeadlinesJuly 26 at 10:43 AM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 25 at 2:49 PM | prnewswire.comKuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law FirmJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 24 at 8:00 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 12, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 10, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 7, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 1, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 30, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJune 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJune 18, 2024 | globenewswire.comInvestigation Into Zentalis Pharmaceuticals, Inc. (ZNTL) Announced byHolzer & Holzer, LLCJune 18, 2024 | globenewswire.comZentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development ProgramJune 3, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 30, 2024 | globenewswire.comZentalis Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of DirectorsMay 23, 2024 | globenewswire.comZentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual MeetingSee More Headlines Receive ZNTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZNTL CUSIPN/A CIK1725160 Webwww.zentalis.com Phone212-433-3791FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$25.00 Low Stock Price Target$4.00 Potential Upside/Downside+146.9%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-292,190,000.00 Net MarginsN/A Pretax Margin-507.56% Return on Equity-46.05% Return on Assets-37.80% Debt Debt-to-Equity RatioN/A Current Ratio9.19 Quick Ratio9.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.18 per share Price / Book0.74Miscellaneous Outstanding Shares71,030,000Free Float66,693,000Market Cap$326.03 million OptionableOptionable Beta1.70 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Kimberly Lynn Blackwell M.D. (Age 55)CEO & Director Comp: $1.17MMr. Cameron S. Gallagher M.B.A. (Age 54)Co-Founder, President, Interim CFO, Interim Treasurer & Director Comp: $892.15kMs. Andrea Paul J.D. (Age 43)Chief Legal Officer & Corporate Secretary Comp: $682.47kDr. Diana F. Hausman M.D. (Age 61)Chief Medical Officer & Director Comp: $38.44kMr. Vincent Vultaggio (Age 41)VP of Finance & Interim Principal Accounting Officer Dr. Mark Lackner Ph.D. (Age 56)Chief Scientific Officer Ms. Kimberly FreemanChief Strategy OfficerDr. Kyle Rasbach Ph.D. (Age 44)Pharm.D., Chief Business Officer Dr. Adrian Jubb M.D.Ph.D., Executive Vice President of Clinical DevelopmentMore ExecutivesKey CompetitorsPrelude TherapeuticsNASDAQ:PRLDCryoportNASDAQ:CYRXIronwood PharmaceuticalsNASDAQ:IRWDArcutis BiotherapeuticsNASDAQ:ARQTDisc MedicineNASDAQ:IRONView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 43,839 shares on 7/26/2024Ownership: 0.470%Values First Advisors Inc.Bought 3,859 shares on 7/19/2024Ownership: 0.105%SG Americas Securities LLCBought 14,152 shares on 7/12/2024Ownership: 0.020%Cam GallagherSold 9,597 sharesTotal: $114,972.06 ($11.98/share)Opaleye Management Inc.Bought 200,000 shares on 5/29/2024Ownership: 0.282%View All Insider TransactionsView All Institutional Transactions ZNTL Stock Analysis - Frequently Asked Questions How have ZNTL shares performed this year? Zentalis Pharmaceuticals' stock was trading at $15.15 at the start of the year. Since then, ZNTL stock has decreased by 70.5% and is now trading at $4.47. View the best growth stocks for 2024 here. How were Zentalis Pharmaceuticals' earnings last quarter? Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) issued its quarterly earnings results on Tuesday, May, 7th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.77) by $0.91. The firm earned $40.56 million during the quarter, compared to the consensus estimate of $35 million. When did Zentalis Pharmaceuticals IPO? Zentalis Pharmaceuticals (ZNTL) raised $131 million in an IPO on Friday, April 3rd 2020. The company issued 7,700,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. Who are Zentalis Pharmaceuticals' major shareholders? Top institutional investors of Zentalis Pharmaceuticals include Bank of New York Mellon Corp (0.47%), Values First Advisors Inc. (0.11%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Matrix Capital Management Comp, Anthony Y Sun, Cam Gallagher, Melissa B Epperly, Diana Hausman, Kimberly Blackwell, David Michael Johnson, Carrie Brownstein, Jan Skvarka, Kevin D Bunker, Dimitris Voliotis and Alexis Pinto. View institutional ownership trends. How do I buy shares of Zentalis Pharmaceuticals? Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Zentalis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR), Zogenix (ZGNX), AbbVie (ABBV), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY) and Clovis Oncology (CLVS). This page (NASDAQ:ZNTL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
